期刊文献+

Ⅰ型组蛋白去乙酰化酶在心肌肥厚中的靶点作用 被引量:1

暂未订购
导出
摘要 组蛋白去乙酰化酶是一种转录后修饰的酶类,可以使组蛋白去乙酰化。Ⅰ型组蛋白去乙酰化酶可促进心肌肥厚发生。在Ⅰ型组蛋白去乙酰化酶中,组蛋白去乙酰化酶2(HDAC2)由肥大刺激和热休克蛋白70诱导活化。活化的HDAC2通过抑制级联信号Krüppel样因子4(KLF4)或肌醇多磷酸磷酸酶-5-f(Inpp5f)触发肥大。因此,调节HDAC2的酶类,例如选择性组蛋白去乙酰化酶抑制剂,被认为是治疗心脏疾病尤其是阻止心肌肥厚的一个重要靶标。该文讨论Ⅰ型组蛋白去乙酰化酶在调节心肌肥厚中所起的关键作用。
出处 《国际心血管病杂志》 2013年第6期359-361,共3页 International Journal of Cardiovascular Disease
  • 相关文献

参考文献25

  • 1Clocchiatti A, Di Giorgio E, Ingrao S, et al. Class IIa HDACs repressive activities on MEF2 depedent transcription are associated with poor prognosis of ER: breast tumors [J]. FASEB, 2013, 27 (3): 942-954.
  • 2Min SK, Koh YH, Park Y, et al. Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas [J]. Korean J Pathol, 2012, 46(2): 142-150.
  • 3Dobaczewski M, Bujak M, Li N, et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction [J]. Circ Res, 2010, 107(3): 418-428.
  • 4Shah RR, Koniski A, Shinde M, et al. Regulation of primitive hematopoiesis by class I histone deacetylases [J]. Dev Dyn, 2013, 242(2): 108-121.
  • 5Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases [J]. Clin Sci, 2013, 124(11) : 651-662.
  • 6Deubzer HE, Schier MC,Oehme I. HDACll is a novel drug target in carcinomas [J]. Int J Cancer, 2013, 132(9) : 2200- 2208.
  • 7Sato T, Kotake D, Hiratsuka M, et al. Enhancement of inflammatory protein expression and nuclear factor Kb (NF Kb) activity by trichostatin A (TSA) in OP9 preadipoeytes [J]. PI:oS One, 2013, 8(3) : e59702.
  • 8Zhao L, Chen CN, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid [J ]. Circulation, 2012, 126(4): 455-467.
  • 9Larsson P, Ulfhammer E, Magnusson M, et al. Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue type plasminogen activator expression [J]. PLoSOne, 2012, 7(2): e31573.
  • 10Von Mevenn F, Porstmann T, Gasser E, et al. Glueagon- induced acetylation of foxa2 regulates hepatic lipid metabolism [J]. Cell Metab, 2013, 17(3): 436-447.

同被引文献27

  • 1Greco CM, Condorelli G. Epigenetic modifications and noneoding RNAs in cardiac hypertrophy and failure [J]. Nat Rev Cardiol, 2015,12(8) :488-497.
  • 2Wang Y, Miao X, Liu Y, et al. Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases [J]. Oxid Med Cell Longer, 2014,2014:641979.
  • 3Sadoul K, Boyault C, Pabion M, et al. Regulation of protein turnover by acetyltransferases and deacetylases [J ]. Biochimie, 2008,90(2) :306-312.
  • 4Yang XJ, Scto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention [J]. Oncogene, 2007,26(37) :5310-5318.
  • 5Mujtaba S, Zeng L, Zhou MM. Structure and acetyl-lysine recognition of the bromodomain [J]. Oncogene, 2007, 26 (37) : 5521-5527.
  • 6Wei JQ, Shehadeh LA, Mitrani JM, et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300 [J]. Circulation, 2008,118 ( 9 ) : 934-946.
  • 7Chen X, Qin L, Liu Z, et al. Knockout of SRC-1 and SRC-3 in mice decreases cardiomyocyte proliferation and causes a noncompaction cardiomyopathy phenotype [J]. Int J Biol Sci, 2015,11 (9) : 1056-1072.
  • 8Li L, Zhu J, Tian J, et al. A role for Gcn5 in cardiomyocyte differentiation of rat mesenchymal stem cells [J]. Mol Cell Biochem, 2010,345(1-2) :309-316.
  • 9Lin W, Srajer G, Evrard YA, et al. Developmental potential of Gcn5(-/-) embryonic stem cells in vivo and in vitro [J]. Dev Dyn, 2007,236(6) : 1547-1557.
  • 10Cao Y, Lu L, Liu M, et al. Impact of epigenetics in the management of cardiovascular disease: a review[J]. Eur Rev Med Pharmacol Sei, 2014,18(20) :3097-3104.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部